Larvol Delta - On-track-to-complete-enrollment-in-the-Phase-2-EFZOCONNECT-study-to-evaluate-the-efficacy-safety-and-tolerability-of-efzofitimod-in-patients-with-limited-or-diffuse-systemic-sclerosis-SSc-or-sclerodermarelated-ILD-SScILD-in-the-first-half-of-2026

Stalaris (efzofitimod) - aTyr Pharma, Kyorin

https://www.globenewswire.com/news-release/2026/05/15/3295781/0/en/aTyr-Pharma-Announces-First-Quarter-2026-Results-and-Provides-Corporate-Update.html

May 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next